Core Platforms

Differentiator: Seamless Integration of Vertical Segments

Avalon achieves and fosters seamless integration of unique verticals to bridge and accelerate innovative research, bio-process development, clinical programs and product commercialization.


Avalon’s upstream innovative research includes

  • “FLASH-CARTM”: RNA-based cellular immunotherapy (candidate AVA-011)
  • Novel therapeutic and diagnostic targets development utilizing QTY-code protein design technology (“AVA-TrapTM”) with the Massachusetts Institute of Technology (MIT).


Avalon’s midstream bio-processing and bio-production facility consists of state-of-the-art, automated GMP and QC/QA infrastructure for standardized bio-manufacturing of clinical-grade cellular products involved in our clinical programs in immune effector cell therapy and regenerative therapeutics.


Avalon’s downstream medical team and facility consists of top-rated affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics.